PURCHASE OF A XENOGEN'S IVIS IMAGING SYSTEM 200 WORKSTATION: CANCER
购买 Xenogen 的 IVIS 成像系统 200 工作站:癌症
基本信息
- 批准号:7335170
- 负责人:
- 金额:$ 12.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-07-01 至 2007-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This subproject is one of many research subprojects utilizing the resources provided by a Shared Instrumentation Grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the grant, which is not necessarily the institution for the investigator. This Shared Instrumentation Grant application requests support to purchase a Xenogen biphotonic workstation for the imaging of whole, small animals. The instrument will be integrated into the existing Englert Image Analysis Facility, which is a shared resource of the Norris Cotton Cancer Center at Dartmouth Medical School. The workstation will provide new technologies to the community of NIH-funded scientists at Dartmouth College, the Thayer School of Engineering, Dartmouth Medical School and Dartmouth-Hitchcock Medical Center. As part of a comprehensive effort to expand whole animal imaging at Dartmouth, we propose the purchase of a Xenogen IVIS" Imaging System. This workstation will permit optical (fluorescence/bioluminescence) imaging of cells and biologicals in small animals and allow to image, in real time, the migration of cancer cells, the biodistribution of therapeutics, pharmacokinetic studies and studies of gene expression in situ. This new technology will allow Dartmouth, NIH-funded scientists to address specific questions that are heretofore unapproachable given existing, available technologies. In addition, because animals can be serially assessed for tumor growth or gene expression, this new technology will greatly reduce the number of animals needed for use in experimentation. The Englert Image Analysis Facility is an established shared resource supported by a number of institutional sources and is directed by a Director, co-director and an Advisory Board. There is extensive scientific and technical expertise at the faculty level for effective development of optical imaging technology. Faculty from the Thayer School of Engineering, who are experts in whole animal imaging and analysis will be an integral part of the development of this technology at Dartmouth. Long-term support and maintenance of the Xenogen workstation will be met by support from the NCI Core Grant to the Norris Cotton Cancer Center, together with users fees as well as institutional support from Dartmouth Medical School. Furthermore, Dartmouth Medical School has committed $50,000 towards the purchase of this instrument. The integration of this instrument will meet an important, needed component in the overall mission to build whole animal imaging technology at Dartmouth. We have identified 12 major and 2 minor users whose research capabilities will be markedly expanded given the availability of the Xenogen workstation. The role of this new technology to meet the needs of the NIH-sponsored specific aims for each of these research programs is presented.
这个子项目是利用由NIH/NCRR资助的共享仪器赠款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金,因此可能会出现在其他CRISE条目中。列出的机构是用于拨款的,而不一定是用于调查人员的机构。此共享仪器授权应用程序请求支持购买Xenogen双光子工作站,用于对整个小动物进行成像。该仪器将被整合到现有的恩格勒图像分析设备中,该设备是达特茅斯医学院诺里斯棉花癌症中心的共享资源。该工作站将为达特茅斯学院、塞耶工程学院、达特茅斯医学院和达特茅斯-希区柯克医学中心的NIH资助的科学家社区提供新技术。作为在达特茅斯扩展整体动物成像的全面努力的一部分,我们建议购买Xenogen IVIS“成像系统”。该工作站将允许对小动物的细胞和生物制品进行光学(荧光/生物发光)成像,并允许实时成像癌细胞的迁移、治疗药物的生物分布、药代动力学研究和原位基因表达研究。这项新技术将使美国国立卫生研究院资助的达特茅斯大学的科学家能够解决迄今为止在现有可用技术下无法解决的具体问题。此外,由于可以对动物的肿瘤生长或基因表达进行连续评估,这项新技术将大大减少实验所需的动物数量。恩格勒特图像分析基金是一项既定的共享资源,得到若干机构来源的支持,由一名主任、联合主任和一个咨询委员会领导。在有效开发光学成像技术方面,在教员层面拥有广泛的科学和技术专长。来自塞耶工程学院的教师是整个动物成像和分析方面的专家,他们将是达特茅斯这项技术开发中不可或缺的一部分。Xenogen工作站的长期支持和维护将由NCI向诺里斯棉花癌症中心提供的核心补助金、使用费以及达特茅斯医学院的机构支持提供。此外,达特茅斯医学院还承诺提供50,000美元用于购买这种仪器。该仪器的集成将满足在达特茅斯建立整个动物成像技术的总体任务中一个重要的、必要的组成部分。我们已经确定了12个主要用户和2个次要用户,由于Xenogen工作站的推出,他们的研究能力将得到显着扩展。这项新技术在满足美国国立卫生研究院赞助的每个研究项目的具体目标方面所起的作用被提出。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RANDOLPH J. NOELLE其他文献
RANDOLPH J. NOELLE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RANDOLPH J. NOELLE', 18)}}的其他基金
Targeting VISTA eradicates large, established PD-1/CTLA-4 resistant tumors
靶向 VISTA 根除大型、已确定的 PD-1/CTLA-4 耐药肿瘤
- 批准号:
9917740 - 财政年份:2017
- 资助金额:
$ 12.51万 - 项目类别:
Targeting VISTA eradicates large, established PD-1/CTLA-4 resistant tumors
靶向 VISTA 根除大型、已确定的 PD-1/CTLA-4 耐药肿瘤
- 批准号:
10170281 - 财政年份:2017
- 资助金额:
$ 12.51万 - 项目类别:
Retinoic acid in gut immune homestatis and infection
视黄酸在肠道免疫稳态和感染中的作用
- 批准号:
8913568 - 财政年份:2015
- 资助金额:
$ 12.51万 - 项目类别:
Retinoic acid in gut immune homestatis and infection
视黄酸在肠道免疫稳态和感染中的作用
- 批准号:
9205215 - 财政年份:2015
- 资助金额:
$ 12.51万 - 项目类别:
VISTA, a novel regulator of immunity and autoimmunity
VISTA,一种新型免疫和自身免疫调节剂
- 批准号:
8840881 - 财政年份:2012
- 资助金额:
$ 12.51万 - 项目类别:
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease
负调节剂作为自身免疫性疾病新疗法的验证
- 批准号:
8314301 - 财政年份:2012
- 资助金额:
$ 12.51万 - 项目类别:
VISTA, a novel regulator of immunity and autoimmunity
VISTA,一种新型免疫和自身免疫调节剂
- 批准号:
8463984 - 财政年份:2012
- 资助金额:
$ 12.51万 - 项目类别:
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease
负调节剂作为自身免疫性疾病新疗法的验证
- 批准号:
8461514 - 财政年份:2012
- 资助金额:
$ 12.51万 - 项目类别:
VISTA, a novel regulator of immunity and autoimmunity
VISTA,一种新型免疫和自身免疫调节剂
- 批准号:
8387505 - 财政年份:2012
- 资助金额:
$ 12.51万 - 项目类别:
Safe and effective anti CD154 antibodies for therapeutic intervention
用于治疗干预的安全有效的抗 CD154 抗体
- 批准号:
8523637 - 财政年份:2012
- 资助金额:
$ 12.51万 - 项目类别: